Ischemic cardiovascular disease is the leading cause of death for both men and women in the US and most other industrialized countries. Most commonly caused by atherosclerosis of the coronary arteries, ischemic cardiovascular disease is characterized by a reduced blood supply to the heart, leading to low oxygen, glucose, and pH levels.
Therapeutic angiogenesis using bone marrow cells has become a promising new field of treatment for ischemic cardiovascular disease (R Laham, et al.). However, maintaining the bone marrow-derived angiogenic cells (BMDACs) under an ischemic microenvironment remains a major obstacle for this treatment.
-Western%20Blot-NB100-105-img0005.jpg "Western Blot: HIF-1 alpha Antibody")
In a new study published in Blood Journal [PMID: 21389314], S Rey, et al. demonstrate that HIF-1 activity can be induced to metabolically reprogram BMDACs, resulting in a significant survival advantage in ischemic tissue. Specifically, dimethyloxalylglycine (DMOG) was used to induce HIF-1 activity, which reduced tissue necrosis and doubled the half-life of BMDACs in ischemic tissue. These findings indicate that a HIF-1-based gene and cell therapy approach will likely enhance the therapeutic efficacy of BMDACs.
Novus Biologicals antibodies against HIF-1 alpha, lactate dehydrogenase A, and PDK1 were used in this study for FACS and WB analysis, respectively. Novus currently offers a wide variety of excellent hypoxia antibodies for use in angiogenesis related research.
Novus Biologicals offers many HIF-1 alpha reagents for your research needs including:
